Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial

Jane A. Cauley(University of Pittsburgh), Larry Norton(Memorial Sloan Kettering Cancer Center), Marc E. Lippman(Georgetown University), Stephen Eckert(Applied Research Associates (United States)), Kathryn A. Krueger(Eli Lilly (United States)), David W Purdie(University of Hull), Jordi Farrerons(Hospital San Juan de la Cruz), Avraham Karasik(Sheba Medical Center), Dan Mellström(Sahlgrenska University Hospital), Kong Wah Ng(The University of Melbourne), J Štěpán(Charles University), Trevor J. Powles(Royal Marsden Hospital), Monica Morrow(Northwestern University), Alberto Costa(European Institute of Oncology), Sheryl L. Silfen(Eli Lilly (United States)), Erin L. Walls(Eli Lilly (United States)), Henry Schmitt(Eli Lilly (United States)), Douglas B. Muchmore(Applied Research Associates (United States)), V. Craig Jordan(Health Outcomes Solutions (United States))
Breast Cancer Research and Treatment
January 1, 2001
Cited by 681

Abstract


Related Papers

No related papers found

Powered by citation graph analysis